Companies › Cytokinetics
3 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 4; Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Aficamten | – | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy; Pediatric; Hypertrophic Cardiomyopathy (HCM) | Nov 2026 |
| Omecamtiv Mecarbil Cardiac myosin activator | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 3 | Heart Failure | Sep 2027 |
| CK-4021586 (ulacamten) | – | Phase 2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06793371 | CK-4021586 (ulacamten) | Phase 2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Cardiovascular | Sep 2026 |
| NCT06081894 | Aficamten | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Cardiovascular | Nov 2026 |
| NCT07600177 | Aficamten | Phase 4 | Hypertrophic Cardiomyopathy (HCM) | Cardiovascular | Dec 2026 |
| NCT06736574 | Omecamtiv Mecarbil | Phase 3 | Heart Failure | Cardiovascular | Sep 2027 |
| NCT06412666 | Aficamten | Phase 2 | Pediatric | Cardiovascular | Jan 2030 |
Cash and short-term investments of $1.6bn on 2026-09-30; operating cash outflow about $576m a year; runway about 33 months at that burn, to Jul 2029; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kardigan Braveheart Bio iVascular S.L.U. Inhibikase Therapeutics Grace Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.